drugset / Trial / NCT02758392
A Study to Evaluate Safety and Tolerability of JNJ-61178104 in Healthy Participants
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and immunogenicity of JNJ-61178104 following a single ascending Intravenous (IV) dose administration and a single Subcutaneous (SC) dose administration in healthy participants.
Timeline
- Start
- 2016-04
- Primary completion
- 2017-01
- Completion
- 2017-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JNJ-61178104 | Unknown | 0.1 mg/kg | Intravenous |
| Subject | JNJ-61178104 | Unknown | 0.3 mg/kg | Intravenous |
| Subject | JNJ-61178104 | Unknown | 1 mg/kg | Intravenous |
| Subject | JNJ-61178104 | Unknown | 3 mg/kg | Intravenous |
| Subject | JNJ-61178104 | Unknown | 10 mg/kg | Intravenous |
Indications
No indication recorded.